Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs BIO-TECHNE Corp — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $79.85, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while iShares Core MSCI Emerging Markets ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| IEMG | TECH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $72.29 |
52-Week Low | $61.27 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $79.99, up 0.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on emerging markets with a 0.09% expense ratio and a 40% technology weighting, driven by AI-related stocks in South Korea and Taiwan. Recent news highlights strong inflows and outperformance versus U.S. benchmarks, though volatility remains elevated.
Outlook is positive due to attractive valuations and growth in emerging markets, but risks include concentration in tech, geopolitical tensions, and higher volatility. Analysts note potential for gains but advise caution after a 39% surge over the past year.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
